uni-leipzig-open-access/json/s41409-022-01867-4

{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T15:21:55Z","timestamp":1705764115953},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1038\/s41409-022-01867-4","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T11:11:01Z","timestamp":1669201861000},"page":"229-232","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA\/DRST experience"],"prefix":"10.1038","volume":"58","author":[{"given":"Peter","family":"Dreger","sequence":"first","affiliation":[]},{"given":"Udo","family":"Holtick","sequence":"additional","affiliation":[]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-1410-4487","authenticated-orcid":false,"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[]},{"given":"Eva","family":"Wagner","sequence":"additional","affiliation":[]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[]},{"given":"Reinhardt","family":"Marks","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-4876-802X","authenticated-orcid":false,"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[]},{"given":"Ulf","family":"Schnetzke","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0001-7025-1735","authenticated-orcid":false,"given":"Christian","family":"Koenecke","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-3828-0031","authenticated-orcid":false,"given":"Malte","family":"von Bonin","sequence":"additional","affiliation":[]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[]},{"given":"Bertram","family":"Glass","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-0748-834X","authenticated-orcid":false,"given":"Claudia D.","family":"Baldus","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-8398-285X","authenticated-orcid":false,"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[]},{"given":"Dimitrios","family":"Mougiakakos","sequence":"additional","affiliation":[]},{"given":"Max","family":"Topp","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0003-2744-5491","authenticated-orcid":false,"given":"Roland","family":"Schroers","sequence":"additional","affiliation":[]},{"given":"Daniel","family":"Wolff","sequence":"additional","affiliation":[]},{"given":"Simone","family":"Thomas","sequence":"additional","affiliation":[]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0001-6052-2618","authenticated-orcid":false,"given":"Wolfgang A.","family":"Bethge","sequence":"additional","affiliation":[]},{"name":"on behalf of the German Lymphoma Alliance (GLA)","sequence":"additional","affiliation":[]},{"name":"the German Stem Cell Transplantation Registry (DRST)","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"1867_CR1","first-page":"349","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, et al. GLA\/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. 2022;140:349\u201358.","journal-title":"Blood"},{"key":"1867_CR2","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood.2019004162","volume":"135","author":"SS Neelapu","year":"2020","unstructured":"Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020;135:2106\u20139.","journal-title":"Blood"},{"key":"1867_CR3","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4:5414\u201324.","journal-title":"Blood Adv"},{"key":"1867_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bjh.18209","volume":"198","author":"A Kuhnl","year":"2022","unstructured":"Kuhnl A, Roddie C, Kirkwood AA, Tholouli E, Menne T, Patel A, et al. A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience. Br J Haematol. 2022;198:492\u2013502.","journal-title":"Br J Haematol."},{"key":"1867_CR5","doi-asserted-by":"publisher","unstructured":"Kwon M, Iacoboni G, Reguera JL, Corral LL, Morales RH, Ortiz-Maldonado V, et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2022. https:\/\/doi.org\/10.3324\/haematol.2022.280805.","DOI":"10.3324\/haematol.2022.280805"},{"key":"1867_CR6","doi-asserted-by":"publisher","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","volume":"28","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, et al. Real-world evidence of axicabtagene ciloleucel for the treatment of large B-cell lymphoma in the United States. Transplant Cell Ther. 2022;28:581.e1\u2013581.e8.","journal-title":"Transplant Cell Ther."},{"key":"1867_CR7","doi-asserted-by":"publisher","first-page":"E427","DOI":"10.1002\/ajh.26330","volume":"96","author":"K Wudhikarn","year":"2021","unstructured":"Wudhikarn K, Bansal R, Khurana A, Hathcock MA, Braksick SA, Bennani NN, et al. Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel. Am J Hematol. 2021;96:E427\u2013E430.","journal-title":"Am J Hematol."},{"key":"1867_CR8","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","volume":"107","author":"R Ram","year":"2022","unstructured":"Ram R, Grisariu S, Shargian-Alon L, Amit O, Bar-On Y, Stepensky P, et al. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study. Haematologica. 2022;107:1111\u20138.","journal-title":"Haematologica"},{"key":"1867_CR9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640\u201354.","journal-title":"N Engl J Med."},{"key":"1867_CR10","doi-asserted-by":"publisher","first-page":"S211","DOI":"10.1097\/01.HS9.0000843736.56298.a7","volume":"6","author":"A Sureda","year":"2022","unstructured":"Sureda A, Westin J, Locke FL, Dickinson M, Ghobadi A, Elsawy M, et al. Clinical and patient reported outcomes in a phase 3 study of Axicabtagene Ciloleucel vs standard-of-care in erlderly patients with relapsed\/refractory large B-cell lymphoma (ZUMA-7) [abstract]. HemaSphere. 2022;6:S211\u2013113.","journal-title":"HemaSphere"},{"key":"1867_CR11","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1182\/bloodadvances.2022007006","volume":"6","author":"A Perez","year":"2022","unstructured":"Perez A, Johnson G, Patel K, Arciola B, Wood A, Bachmeier CA, et al. Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood Adv. 2022;6:3970\u20133.","journal-title":"Blood Adv"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01867-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01867-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01867-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T13:07:39Z","timestamp":1675688859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01867-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1867"],"URL":"http:\/\/dx.doi.org\/10.1038\/s41409-022-01867-4","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":["Transplantation","Hematology"],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"10 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PD consultancy for AbbVie, AstraZeneca, bluebird bio, Gilead, Janssen, Miltenyi, Novartis, Riemser, Roche; speakers bureau for AbbVie, AstraZeneca, Gilead, Novartis, Riemser, Roche; research support from Riemser; UH honoraria from Novartis, Gilead, BMS, Miltenyi, Roche; MS research support Amgen, BMS, Gilead, Miltenyi, MorphoSys, Novartis, Roche, Seagen, Advisory Board Amgen, BMS, Gilead, Janssen, Novartis, Pfizer, Seagen, Speaker\u2019s Bureau Amgen, BMS, Gilead, Novartis, Pfizer, Takeda; BvT advisor or consultant for BMS\/Celgene, Incyte, Miltenyi, Novartis, Pentixafarm, Amgen, Pfizer, Takeda, MSD, Gilead Kite, honoraria from AstraZeneca, Novartis, Roche, Takeda, and MSD, research funding from Novartis, MSD, Takeda, travel support from AbbVie, AstraZeneca, Kite-Gilead, MSD, Takeda, Novartis; FA honoraria from Novartis, Gilead, BMS, Janssen, Takeda, Therakos\/Mallinckrodt, research funding from Therakos\/Mallinckrodt; GW honoraria Gilead, Novartis, Takeda, Clinigen, Amgen; OP honoraria or travel support from Astellas, Gilead, Jazz, MSD, Neovii Biotech, Novartis, Pfizer and Therakos, research support from Gilead, Incyte, Jazz, Neovii Biotech and Takeda, advisory boards of Jazz, Gilead, MSD, Omeros, Priothera, Shionogi and SOBI; US advisory board Novartis; CK Advisory boards: Abbvie, Amgen, BMS, EusaPharm, GSK, Janssen, Kite\/Gilead, Medigene, Novartis, Roche, Sanofi, Takeda, Pfizer, Incyte; MvB honoraria and travel funds Gilead, Novartis, Janssen, Takeda, Daiichi Sanky\u014d; MSt honoraria Kite\/Gilead, Jazz, MSD, Novartis, Pfizer, BMS\/Celgene; CDB received honoraria and travel funds from BMS, Amgen, Novartis, Jazz, Gilead, Janssen; VV honoraria and travel funds for Gilead, honoraria and consultancies for Novartis, Gilead, BMS\/Celgene; DM consultancies for AbbVie, Roche, BMS, Hexal, Novartis, MSD, Celgene, Janssen-Cilag, Pfizer, Astra-Zeneca, and Jazz Pharma; DW honoraria from Behring, BMS, Gilead, Novartis, Takeda; research support from Novartis; ST honoraria and travel funds Abbvie, BMS\/Celgene, EUSA Pharma, Janssen, Gilead, Medigene, Novartis, Pfizer; Research funding BMS\/Celgene, Gilead; NK honoraria Kite\/Gilead, Jazz, MSD, Neovii Biotech, Novartis, Riemser, Pfizer, BMS Research support from Neovii, Riemser, Novartis, BMS; WB honoraria and travel funds Gilead, Novartis, Miltenyi and Janssen, Research grants Miltenyi. BG, RM, RS, MT and EW declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}